SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3

QR Code

SOFOSBUVIR-VELPATASVIR THERAPY IN THE TREATMENT OF CHRONIC HEPATITIS C GENOTYPE 3

Objective: To determine the efficacy and safety of sofosbuvir-velpatasvir combination therapy in treatment of chronic hepatitis C genotype 3. Study Design: Prospective cohort study. Place and Duration of Study: Department of Medicine, Combined Military Hospital Lahore, from Mar 2018 to Oct 201...

Full description

Saved in:

Bibliographic Details
Main Authors:	Arif Qayyum Khan, Hala Mansoor, Samina Fida, Saba Saif, Javed Iqbal, Muhammad Siddique
Format:	article
Language:	EN
Published:	Army Medical College Rawalpindi 2021
Subjects:	hepatitis c sustained virological response sofosbuvir velpatasvir Medicine R Medicine (General) R5-920
Online Access:	https://doaj.org/article/2841f49f314e4c478be8efc7acad314a
Tags:	Add Tag No Tags, Be the first to tag this record!

Similar Items

Safety and Efficacy of Sofosbuvir and Daclatasvir in The Treatment of Chronic HCV Infection in Elderly Egyptian Patients
by: Mohamed G. Mohamed, et al.
Published: (2021)

Daclatasvir–sofosbuvir combination therapy with or without ribavirin for hepatitis C virus infection: from the clinical trials to real life
by: Pol S, et al.
Published: (2016)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
by: Arif Qayyum Khan, et al.
Published: (2020)

EFFICACY OF FIRST AVAILABLE DIRECT-ACTING ANTIVIRAL AGENT IN TREATMENT OF CHRONIC HEPATITIS C; RESULTS FROM A SINGLE CENTRE IN PAKISTAN
by: Arif Qayyum Khan, et al.
Published: (2020)

Efficacy and safety of sofosbuvir-based therapies in patients with advanced liver disease in a real-life cohort
by: Kutala BK, et al.
Published: (2017)

Effectiveness of direct-acting antiviral drugs against hepatitis C virus: predictive factors of response to the treatment
by: María E. Cárdaba-García, et al.
Published: (2021)

ENHANCEMENT SPECTRAL RESOLUTION FOR THE PREDICTION AMOUNT OF SOFOSBUVIR AND LEDIPASVIR USING LEAST SQUARES SUPPORT VECTOR MACHINE AND ARTIFICIAL NEURAL NETWORKS IN PHARMACEUTICAL FORMULATION
by: Safakhoo,Negin, et al.
Published: (2019)

Estimating the net value of treating hepatitis C virus using sofosbuvir-velpatasvir in India.
by: David E Bloom, et al.
Published: (2021)

Association of sustained virologic response with reduced progression to liver cirrhosis in elderly patients with chronic hepatitis C
by: Tseng CW, et al.
Published: (2016)

The efficacy of direct-acting antiviral therapy in patients with chronic hepatitis C
by: Irina RUSU, et al.
Published: (2020)

Aspartate aminotransferase to platelet ratio index and sustained virologic response are associated with progression from hepatitis C associated liver cirrhosis to hepatocellular carcinoma after treatment with pegylated interferon plus ribavirin
by: Ng KJ, et al.
Published: (2016)

Possible acute rejection associated with the use of the new antihepatitis C virus medications
by: Khaled Ar Karkout, et al.
Published: (2019)

Synthetic vaccine affords full protection to mice against lethal challenge of influenza B virus of both genetic lineages
by: Caroline Gravel, et al.
Published: (2021)

Prestimulation of CD2 confers resistance to HIV-1 latent infection in blood resting CD4 T cells
by: Sijia He, et al.
Published: (2021)

IL-17A reprograms intestinal epithelial cells to facilitate HIV-1 replication and outgrowth in CD4+ T cells
by: Tomas Raul Wiche Salinas, et al.
Published: (2021)

Influenza A induces lactate formation to inhibit type I IFN in primary human airway epithelium
by: Jacob Thyrsted, et al.
Published: (2021)

Merkel cell polyomavirus T-antigens regulate DICER1 mRNA stability and translation through HSC70
by: Jiwei Gao, et al.
Published: (2021)

Effect of Successful Direct Acting Antivirals Therapy on Liver Stiffness in Patients with Chronic HCV Infection
by: Ibrahim Anam Ezzelregal, et al.
Published: (2020)

Partial resistance of SARS-CoV-2 Delta variants to vaccine-elicited antibodies and convalescent sera
by: Takuya Tada, et al.
Published: (2021)

A Novel Standard for Hepatocellular Carcinoma Screening Intensity After Hepatitis C Elimination
by: Miyasaka A, et al.
Published: (2021)

Snake Deltavirus Utilizes Envelope Proteins of Different Viruses To Generate Infectious Particles
by: Leonora Szirovicza, et al.
Published: (2020)

Decreasing racial disparity with the combination of ledipasvir–sofosbuvir for the treatment of chronic hepatitis C
by: Naylor PH, et al.
Published: (2017)

Identification of a Novel Deltavirus in Boa Constrictors
by: Udo Hetzel, et al.
Published: (2019)

Virology journal
Published: (2004)

The Heteroaryldihydropyrimidine Bay 38-7690 Induces Hepatitis B Virus Core Protein Aggregates Associated with Promyelocytic Leukemia Nuclear Bodies in Infected Cells
by: Andrew D. Huber, et al.
Published: (2018)

The impact of viral mutations on recognition by SARS-CoV-2 specific T cells
by: Thushan I. de Silva, et al.
Published: (2021)

Archives of virology

Endonuclease-based genotyping of the RBM as a method to track the emergence or evolution of SARS-CoV-2 variants
by: Eva Lopez, et al.
Published: (2021)

Role of ledipasvir/sofosbuvir combination for genotype 1 hepatitis C virus infection
by: Sundaram V, et al.
Published: (2016)

Interrelationship of hepatitis C virus genotypes with patient characteristics in Bahrain
by: Abdulla MA, et al.
Published: (2017)

Advances in virology

Ombitasvir, paritaprevir, and ritonavir with peginterferon-α2a plus ribavirin in treatment-experienced patients with chronic hepatitis C virus genotype 1 infection
by: Bernstein D, et al.
Published: (2019)

Mouse and Human Monoclonal Antibodies Protect against Infection by Multiple Genotypes of Japanese Encephalitis Virus
by: Estefania Fernandez, et al.
Published: (2018)

Functional differences among the spike glycoproteins of multiple emerging severe acute respiratory syndrome coronavirus 2 variants of concern
by: Qian Wang, et al.
Published: (2021)

Directly observed therapy at opioid substitution facilities using sofosbuvir/velpatasvir results in excellent SVR12 rates in PWIDs at high risk for non-adherence to DAA therapy.
by: Caroline Schmidbauer, et al.
Published: (2021)

Hepatitis research and treatment

Prevalencia de los Virus de Hepatitis en las Hepatitis Agudas en Niños
by: Zacarías S,José, et al.
Published: (1983)

SARS CoV-2 Delta variant exhibits enhanced infectivity and a minor decrease in neutralization sensitivity to convalescent or post-vaccination sera
by: Alona Kuzmina, et al.
Published: (2021)